D0974 | lanatoside c
C
C01AA06 Lanatoside c
[C01AA] Digitalis glycosides
[C01A] CARDIAC GLYCOSIDES
[C01] CARDIAC THERAPY
[C] Cardiovascular system
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 0.78±0.14 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 0.31 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | rat | hepatocytes | MMP assay | Negative | IC50 | 163 | ||
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
 |
Danger |
Aggregated GHS information provided by 43 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H301 (95.35%): Toxic if swallowed [Danger Acute toxicity, oral] H311 (93.02%): Toxic in contact with skin [Danger Acute toxicity, dermal] H331 (93.02%): Toxic if inhaled [Danger Acute toxicity, inhalation] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P261, P264, P270, P271, P280, P301+P310, P302+P352, P304+P340, P311, P312, P321, P322, P330, P361, P363, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| (3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide | 17575-22-3 | 3-((O beta-D-Glucopyranosyl-(1-4)-O-3beta-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12beta,14-dihydroxy-5beta-card-20(22)-enolide |
| 5RR3JFZ771 | AS-35298 | C-23591 |
| CCG-220656 | CHEMBL506569 | CS-4548 |
| Card-20(22)-enolide, 3-((O-beta-D-glucopyranosyl-(1-4)-O-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- (9CI); | Cedilanid | Ceglunate |
| Celanidum | D01972 | DB13467 |
| DSSTox_CID_3198 | DSSTox_GSID_23198 | DSSTox_RID_76921 |
| DTXSID7023198 | Digilanid C | Digilanogen C (TN) |
| EINECS 241-546-1 | Glycoside obtained from the leaves of Digitalis lanata Ehrh | HMS3714C13 |
| HY-B1030 | Isolanid | J-011131 |
| JAYAGJDXJIDEKI-PTGWOZRBSA-N | LANATOSIDE-C | Lanatosid C [German] |
| Lanatoside C (Digoxin Impurity H) | Lanatoside C (JAN/INN) | Lanatoside C [INN:BAN:DCF:JAN:NF] |
| Lanatoside C, >=95% | Lanatosido C | Lanatosido C [INN-Spanish] |
| Lanatosidum C | Lanatosidum C [INN-Latin] | MFCD00869432 |
| NCGC00094932-01 | NSC 119991 | Q6482953 |
| SCHEMBL44110 | Tox21_111361 | UNII-5RR3JFZ771 |
| ZINC253387889 | lanatoside C | s5554 |